Key result
Lifelong proton pump inhibitor cotherapy in patients with CHD taking low-dose aspirin reduced lifetime UGIB events (3.1% vs 9.5%) and was cost-effective at over-the-counter prices.
Why the study?
Does proton pump inhibitor cotherapy improve cost-effectiveness and reduce upper gastrointestinal bleeding in patients with coronary heart disease taking long-term low-dose aspirin?
Does proton pump inhibitor cotherapy improve cost-effectiveness and reduce upper gastrointestinal bleeding in patients with coronary heart disease taking long-term low-dose aspirin?
Absolute Event Rate: 3.1% vs 9.5%
Over-the-counter PPI cotherapy is cost-effective for average-risk patients taking low-dose aspirin for secondary cardiovascular prevention, while prescription-cost PPI is cost-effective only for high-risk patients.
No takes yet. Share an insight, caveat, or question.
May support OTC PPI cotherapy in average-risk CHD patients on aspirin; leaves open prospective validation of UGIB reduction and cost-effectiveness.
Sameer D. Saini (2008) studied Coronary heart disease (CHD). Proton pump inhibitor (PPI) cotherapy vs. Aspirin (ASA) alone was evaluated on Lifetime upper gastrointestinal bleeding (UGIB) events. Lifelong proton pump inhibitor cotherapy in patients with CHD taking low-dose aspirin reduced lifetime UGIB events (3.1% vs 9.5%) and was cost-effective at over-the-counter prices.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: